Adding Tucatinib in First-Line Maintenance Boosts PFS in HER2-Positive Breast Cancer

(MedPage Today) — At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and pertuzumab (Perjeta) maintenance…